MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation

Reuters11-07

MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation

Mind Medicine (MindMed) Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581043641?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581043641","market":"us","top_or_hot":-1,"title":"MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4547","symbol_name":"WSB热门概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL4gWQ53:1","article_id":"2581043641","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581043641","pubTimestamp":1762464542,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mind Medicine  Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder  and major depressive disorder . The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4547":"WSB热门概念","BK4007":"制药","MNMD":"Mind Medicine (MindMed) Inc."},"translate_title":"MindMed在新的公司演示中展示了后期管道进展和精神药物里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":0.9},"content_text":"MindMed Showcases Late-Stage Pipeline Progress and Psychiatric Drug Milestones in New Corporate Presentation\n    \n\nMind Medicine (MindMed) Inc. has released a corporate presentation highlighting ongoing developments in its late-stage pipeline focused on brain health, particularly targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company reports that its lead clinical program, MM120 ODT, is currently the subject of Phase 3 studies in both indications, with three Phase 3 topline readouts anticipated in 2026. MindMed states that it has a strong financial position, with cash and investments totaling $209.1 million as of September 30, 2025, and an additional $242.8 million raised in October 2025, supporting operations into 2028. The presentation also notes issued patents for MM120 ODT covering formulation, manufacturing, and treatment methods, with patent protection through 2041. Upcoming milestones include Phase 3 readouts for GAD and MDD programs, as well as the initiation of further studies. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581043641","isCrawlerRequest":true}